Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04980482 · ClinicalTrials.gov registry record · Phase 2
Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection
A Phase 2 study, sponsored by Arbutus Biopharma Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT04980482 is a Phase 2 study that has completed, run by Arbutus Biopharma Corporation. The registered enrollment target is 43 participants.
The verdict
NCT04980482, a Phase 2 study, has completed, sponsored by Arbutus Biopharma Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This is a randomized, open label, multicenter Phase 2 study investigating the safety and antiviral activity of AB-729 in combination with ongoing NA therapy and short courses of Peg-IFNα-2a in subjects with CHB.
Interventions
- DRUG AB-729
- DRUG Peg-IFNα-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2021-10-29 |
| Est. Completion | 2025-05-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04980482
The ClinicalTrials.gov registry entry for NCT04980482 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arbutus Biopharma Corporation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AB-729 is the first listed.
NCT04980482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04980482 about?
NCT04980482 is a clinical study titled "Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection". This is a randomized, open label, multicenter Phase 2 study investigating the safety and antiviral activity of AB-729 in combination with ongoing NA therapy and short courses of Peg-IFNα-2a in subjects with CHB.
What is the current status of trial NCT04980482?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2021-10-29. Estimated completion is 2025-05-21.
What interventions are being tested in trial NCT04980482?
The interventions under investigation include: AB-729 (DRUG), Peg-IFNα-2a (DRUG).
Who is sponsoring clinical trial NCT04980482?
This trial is sponsored by Arbutus Biopharma Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.